Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Transcriptomics of type 2 diabetic and healthy human neutrophils

Fig. 3

Resolvin E1 treatment has a stronger impact on gene expression in T2D relative to healthy neutrophils. Number of genes differentially expressed (uncorrected p < 0.05) by resolvin E1 (RvE1) treatment dose (0 nM, 1 nM, 10 nM, or 100 nM) across groups: A healthy only, B T2D only, C T2D (higher dose) vs. healthy (lower dose) in cultured neutrophils (N = 3 T2D, N = 3 healthy). D Number of genes differentially expressed (uncorrected p < 0.05) in healthy, T2D and T2D vs. healthy groups, comparing low (1 nM vs. 0 nM) to high (100 nM vs. 0 nM) RvE1 dose. E Bean plots of the relative abundance of gene expression (line at mean) of the significant differentially expressed genes (LILRB5 and AKR1C1; FDR-corrected p < 0.05) and top genes (RN7SL2, LILRB2, and NECTIN2). Samples were plotted for T2D vs. healthy individuals. T2D, type 2 diabetes

Back to article page